Amgen describes MariTide, also called maridebart cafraglutide, as an investigational therapy being studied in the Phase 3 MARITIME program. That is a different status from an approved prescription product available through ordinary clinical care.
A comparison with Wegovy or Zepbound should begin with that distinction. Research announcements are not product approvals, routine prescribing information, or proof that an online seller can supply the therapy.
Read development claims in context
A sponsor announcement describes ongoing research and potential treatment characteristics. It does not establish the final benefit-risk assessment, approved indication, or commercial product instructions.
Cross-trial percentages can involve different populations, study designs, and outcome definitions. They should not be turned into a simple provider ranking or a personal prediction.
Separate research from current treatment
Wegovy and Zepbound have official product information for approved uses. A clinician can discuss whether an available approved treatment is appropriate. An investigational study pathway has separate eligibility and oversight.
Do not purchase an unidentified online product advertised as a research therapy for self-treatment. Ask the clinical team about legitimate research information if that is your interest.
Compare today’s programs honestly
Our semaglutide and tirzepatide pages compare current public clinical offers. They do not imply access to MariTide.
Use official sponsor and trial information to understand research status, and current prescribing information to discuss available products. Keep the two decisions separate.
Continue your comparison
Compare the GLP-1 programs, read the CoreAge Rx review, and use the program table to prepare questions about the complete offer.
Sources & offer details
Public information retrieved on October 1, 2026. Provider statements describe the advertised offer; they do not independently establish treatment outcomes.